A Phase II Study of Daunomycin and Ara-C Given by Continuous IV Infusion with PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older
Research committees
Treatment
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
2017
PMid: PMID28222251; PMC5705230
2015
PMid: PMID25113226 | PMC number: PMC4318722
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
PMid: PMID25527568 | PMC number: PMC4349271
2014
Unsuccessful cytogenetic analysis is a poor prognostic feature in acute myeloid leukemia
PMid: PMID24383844 | PMC number: PMC4117470
PMid: PMID23760400 | PMC number: PMC4457325
2013
PMid: PMID23325837 | PMC number: PMC3612855
2012
Impact of residual normal metaphases in core binding factor acute myeloid leukemia
PMid: PMID21928314 | PMC number: PMC3490403
Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia
PMid: PMID22315487 | PMC number: PMCID3436242
2011
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]
Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]
Prognostic import of French-American-British (FAB) system as embedded in 2008 revision of World Health Organization classification of AML
Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
PMid: PMID21969499 | PMC number: PMC3221524
2010
The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study
PMid: PMID20562328 | PMC number: PMC3709629
Influence of residual normal metaphases in patients with monosomal karyotype